NextCure, Inc. (NXTC): Other Events
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE NEXTCURE, INC. ) ) ) C.A. No. 2026-____-_____ verified petition for relief pursuant to 8 del. c. § 205 Petitioner NextCure, Inc. (“NextCure” or the “Company”), by and through its undersigned co
How this was made
The 30-second read
Why it matters
The outcome will determine whether the 2025 split stands and whether the planned 2026 split and business combination can proceed, influencing shareholder value.
Market read
Legal validation is crucial for NextCure's capital structure and pending merger, creating short‑term price sensitivity.
What to watch
Potential impact of the pending business combination with Avere Therapeutics and any related regulatory approvals.
Background
NextCure, a clinical‑stage biopharma, previously completed a 2025 reverse split after shareholder approval under the Votes Cast Standard. New Delaware law changes raise questions about the amendment's validity, prompting a court petition.
Ticker impact
SEC 8‑K filing details a Delaware court petition to validate the 2025 reverse stock split amendment and related shares, introducing legal uncertainty for the upcoming 2026 reverse split and business combination.
Short‑term volatility expected; upside if court validates, downside if rejected.
The filing is the first public disclosure of the legal challenge; market reaction will depend on court outcome and its effect on the planned transaction.
Market effects
May affect other biotech micro‑caps pursuing reverse splits to meet exchange listing standards.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; primarily a company‑specific legal matter.
Counterpoint
If the court denies validation, the stock could experience a sharp decline, presenting a short opportunity.
Key entities
- companyNextCure, Inc.
Biopharma filing the court petition.
- companyAvere Therapeutics, Inc.
Proposed merger partner.
